Services >> ADME / Tox >> In Vitro Toxicity

Identify and resolve potential liability issues early in drug discovery

Sidebar Image

undefined

Drug toxicity is the major reason for withdrawal of approved drugs from the market, with hepatotoxicity and cardiotoxicity being the top two reasons for withdrawal. While toxicity testing has been traditionally completed in the preclinical phase, it has become obvious that a failure at this stage results in significant setbacks and economic loss.

To address the challenge, Eurofins offers a panel of in vitro toxicology and safety pharmacology assays that are designed for the early stages of drug discovery by utilizing cutting-edge technologies, such as conventional and automated patch clamp and high content analysis (HCA). Importantly, you have immediate access to these assays without major capital and time investment to establish these assays in-house.

Designed with regulatory guidance and recommendations in mind, our assays are valuable for evaluating compound liabilities early in the drug discovery process. Applying such a strategy to your drug discovery program has the benefit of determining whether it is most appropriate to switch to other lead series at a stage in which there is no significant loss in project time and investment.

   

undefined
undefined
undefined
undefined
undefined

Advantages of in vitro toxicity assessment with Eurofins

  • Diverse cytoxocity assays covers a range of potentially toxic events, including hepatotoxicity and cardiotoxicity
  • Our assays are designed with regulatory guidances, ICH S7B & ICH S2(R1), in mind
  • Cutting-edge technologies, like HCA, provide a comprehensive and multi-parametric analysis of toxicity

undefined

Figure 1. Multi-parametric testing of cerivastatin toxicity in HepG2 cells

Cerivastatin treatment decreased cell number and caused nuclei to shrink (white arrows) and mitochondrial membrane potential to decrease. Cerivastatin also increased the release of intracellular calcium and membrane permeability. Together these five parameters demonstrate an adverse profile for cerivastatin, a drug withdrawn from the market.